Identification
Name Sulfametopyrazine
Accession Number DB00664 (APRD00517)
Type small molecule
Description Long-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria. [PubChem]
Structure
Categories (*)
Molecular Weight 280.303
Groups approved
Monoisotopic Weight 280.06301096
Pharmacology
Indication For the treatment of urinary tract infection and chronic bronchitis.
Mechanism of action Sulfametopyrazine is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. Para-aminobenzoic acid (PABA), a substrate of the enzyme is prevented from binding. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.
Absorption Not Available
Protein binding Not Available
Biotransformation Not Available
Route of elimination Not Available
Toxicity Not Available
Affected organisms
  • Gram negative, positive bacteria and plasmodium
Interactions
Drug Interactions Not Available
Food Interactions Not Available
Dihydropteroate synthetase
Name Dihydropteroate synthetase
Gene Name Not Available
Pharmacological action yes
Actions inhibitor
References
  • Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. - Pubmed
  • Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. - Pubmed
  • Brumfitt W, Hamilton-Miller JM: Reassessment of the rationale for the combinations of sulphonamides with diaminopyrimidines. J Chemother. 1993 Dec;5(6):465-9. - Pubmed
DTHybrid score 1.0586